latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/johnson-johnson-rolls-out-early-stage-human-trials-for-covid-19-vaccine-59558448 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Johnson & Johnson rolls out early-stage human trials for COVID-19 vaccine

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Johnson & Johnson rolls out early-stage human trials for COVID-19 vaccine

Johnson & Johnson commenced a phase 1/2a clinical trials of its investigational coronavirus vaccine Ad26.COV2.S.

The New Brunswick, N.J.-based healthcare conglomerate said the first healthy volunteer has been dosed in Belgium, with more than a thousand adults enrolled in the trials that are also taking place in the U.S.

Mathai Mammen, global head of research and development at J&J's Janssen Pharmaceutical Cos. division, announced the launch of the human clinical trials via his LinkedIn page on July 23.

In June, J&J said it is in talks with the National Institutes of Allergy and Infectious Diseases to begin a phase 3 trial to evaluate the vaccine ahead of its original schedule, based on results from phase 1 studies and regulatory approvals.

Janssen also previously signed a partnership with the U.S. Department of Health & Human Services' Biomedical Advanced Research and Development Authority to develop the vaccine. J&J has a five-year deal with Gaithersburg, Md.-based Emergent BioSolutions Inc. to produce the drug substance for its vaccine.

As of July 23, more than 15.2 million people have contracted the coronavirus worldwide, resulting in about 624,100 deaths, data from Johns Hopkins University's Center for Systems Science and Engineering showed. In the U.S. alone, there have been about 3.9 million confirmed cases, with the death toll at 143,100.

READ MORE: Sign up for our weekly coronavirus newsletter here, and read our latest coverage on the crisis here.

SNL Image